Bimonthly Survey

Please indicate if you have used resources and/or trainings from any of the following in the past 12 months.
Select all that apply

Description

Image
image

Join the Midwest AETC for this webinar on transforming HIV prevention.

Objectives

  • Describe HIV prevention options, including currently approved oral and injectable PrEP options.
  • Explain the mechanism of action, pharmacokinetics, dosing, safety, and efficacy of cabotegravir and lenacapavir for PrEP.
  • Compare the advantages and limitations of long-acting, injectable PrEP.
  • Discuss the HIV PrEP pipeline, including longer-acting agents and novel delivery systems.

Speaker

Emily Drwiega, PharmD, BCIDP, BCPS, AAHIVP
Visiting Clinical Assistant Professor/Clinical Pharmacist
UIC College of Pharmacy